NO982913L - Kinolin- og kinazolinforbindelser nyttige i terapi - Google Patents

Kinolin- og kinazolinforbindelser nyttige i terapi

Info

Publication number
NO982913L
NO982913L NO982913A NO982913A NO982913L NO 982913 L NO982913 L NO 982913L NO 982913 A NO982913 A NO 982913A NO 982913 A NO982913 A NO 982913A NO 982913 L NO982913 L NO 982913L
Authority
NO
Norway
Prior art keywords
optionally substituted
group
ring
alkoxy
quinoline
Prior art date
Application number
NO982913A
Other languages
English (en)
Norwegian (no)
Other versions
NO982913D0 (no
Inventor
Alan John Collis
David Nathan Abraham Fox
Julie Newman
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of NO982913D0 publication Critical patent/NO982913D0/no
Publication of NO982913L publication Critical patent/NO982913L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO982913A 1995-12-23 1998-06-22 Kinolin- og kinazolinforbindelser nyttige i terapi NO982913L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9526546.8A GB9526546D0 (en) 1995-12-23 1995-12-23 Compounds useful in therapy
PCT/EP1996/005609 WO1997023462A1 (en) 1995-12-23 1996-12-05 Quinoline and quinazoline compounds useful in therapy

Publications (2)

Publication Number Publication Date
NO982913D0 NO982913D0 (no) 1998-06-22
NO982913L true NO982913L (no) 1998-07-30

Family

ID=10786091

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982913A NO982913L (no) 1995-12-23 1998-06-22 Kinolin- og kinazolinforbindelser nyttige i terapi

Country Status (34)

Country Link
US (3) US6103738A (cs)
EP (1) EP0877734B1 (cs)
JP (1) JP3070958B2 (cs)
KR (1) KR19990076693A (cs)
AP (1) AP715A (cs)
AR (1) AR005166A1 (cs)
AT (1) ATE194598T1 (cs)
AU (1) AU708979B2 (cs)
BG (1) BG102559A (cs)
BR (1) BR9612263A (cs)
CA (1) CA2236814C (cs)
CO (1) CO4480106A1 (cs)
CZ (1) CZ197698A3 (cs)
DE (1) DE69609353T2 (cs)
DK (1) DK0877734T3 (cs)
ES (1) ES2151192T3 (cs)
GB (1) GB9526546D0 (cs)
GR (1) GR3034225T3 (cs)
HN (1) HN1996000082A (cs)
HR (1) HRP960616A2 (cs)
HU (1) HUP9903560A3 (cs)
IS (1) IS4731A (cs)
MA (1) MA26414A1 (cs)
NO (1) NO982913L (cs)
NZ (1) NZ325248A (cs)
OA (1) OA10703A (cs)
PL (1) PL327610A1 (cs)
PT (1) PT877734E (cs)
SK (1) SK81698A3 (cs)
TN (1) TNSN96161A1 (cs)
TR (1) TR199801195T2 (cs)
WO (1) WO1997023462A1 (cs)
YU (1) YU68896A (cs)
ZA (1) ZA9610784B (cs)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526546D0 (en) * 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
GB9711220D0 (en) * 1997-05-30 1997-07-23 Isis Innovation Antiarrhythmic agents
GB9711650D0 (en) * 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy
KR100602929B1 (ko) * 2000-08-31 2006-07-20 에프. 호프만-라 로슈 아게 알파-1 아드레날린성 길항제로서 퀴나졸린 유도체
US6900220B2 (en) 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
CA2432578C (en) * 2001-01-02 2008-04-01 F. Hoffmann-La Roche Ag Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
US6734303B2 (en) 2001-05-18 2004-05-11 Pfizer Inc. Process for the production of quinazolines
GB0206033D0 (en) 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
MXPA05002004A (es) 2002-09-26 2005-04-28 Pfizer Derivados de pirazol.
HRP20080541T3 (en) 2003-04-23 2008-12-31 Glaxo Group Limited Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
WO2005030131A2 (en) * 2003-09-23 2005-04-07 Replidyne, Inc Bis-quinazoline compounds for the treatment of bacterial infections
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
CA2881078C (en) * 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
US8986713B2 (en) * 2006-05-12 2015-03-24 W. L. Gore & Associates, Inc. Medical device capable of being compacted and expanded having anti-thrombin III binding activity
US8021677B2 (en) 2006-05-12 2011-09-20 Gore Enterprise Holdings, Inc. Immobilized biologically active entities having a high degree of biological activity
US20080279909A1 (en) * 2006-05-12 2008-11-13 Cleek Robert L Immobilized Biologically Active Entities Having A High Degree of Biological Activity Following Sterilization
US8496953B2 (en) * 2006-05-12 2013-07-30 W. L. Gore & Associates, Inc. Immobilized biologically active entities having a high degree of biological activity following sterilization
US9114194B2 (en) * 2006-05-12 2015-08-25 W. L. Gore & Associates, Inc. Immobilized biologically active entities having high biological activity following mechanical manipulation
BRPI0808772A2 (pt) 2007-03-14 2014-08-12 Exelixis Inc Inibidores da via de hedgehog
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
BRPI0922010A2 (pt) * 2008-11-14 2015-12-15 Hoffmann La Roche dervivados de quinazolina como antagonistas receptores de nk3
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
SI3330255T1 (sl) 2009-03-20 2021-03-31 Vertex Pharmaceuticals Incorporated Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi
CA2756376A1 (en) * 2009-03-23 2010-09-30 Cipla Limited Process for the preparation of doxazosin and salts thereof
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2473487B1 (en) 2009-09-03 2016-10-26 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US8591932B2 (en) * 2009-09-17 2013-11-26 W. L. Gore & Associates, Inc. Heparin entities and methods of use
CA2828797C (en) 2011-03-11 2020-03-10 Gore Enterprise Holdings, Inc. Single point attachment of heparin to hyperbranched polymers and coatings thereof
US20140309184A1 (en) * 2011-09-21 2014-10-16 University Of South Alabama Methods and compositions for the treatment of ovarian cancer
EP2819670B1 (en) 2012-02-27 2026-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical Composition and Their Administration
JP6377245B2 (ja) * 2014-03-24 2018-08-22 グアンドン ジョンシェン ファーマシューティカル カンパニー リミテッド Ｓｍｏ阻害剤としてのキノリン誘導体
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
MX2018016046A (es) 2016-06-27 2019-05-02 Achillion Pharmaceuticals Inc Quinazolina y compuestos indol para tratar trastornos medicos.
WO2020150473A2 (en) * 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
BR112021013924A2 (pt) * 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR79603B (cs) * 1982-07-24 1984-10-31 Pfizer
GB8506174D0 (en) * 1985-03-09 1985-04-11 Pfizer Ltd 4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives
GB8814458D0 (en) * 1988-06-17 1988-07-20 Wyeth John & Brother Ltd Heterocyclic compounds
GB9526546D0 (en) * 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy

Also Published As

Publication number Publication date
CO4480106A1 (es) 1997-07-09
IS4731A (is) 1998-04-29
AU1371997A (en) 1997-07-17
AU708979B2 (en) 1999-08-19
BG102559A (en) 1999-03-31
HN1996000082A (es) 1997-06-30
GB9526546D0 (en) 1996-02-28
CA2236814A1 (en) 1997-07-03
AR005166A1 (es) 1999-04-14
NO982913D0 (no) 1998-06-22
WO1997023462A1 (en) 1997-07-03
US20020049322A1 (en) 2002-04-25
GR3034225T3 (en) 2000-12-29
DE69609353T2 (de) 2000-12-07
ATE194598T1 (de) 2000-07-15
HRP960616A2 (en) 1998-06-30
HUP9903560A3 (en) 2000-07-28
ES2151192T3 (es) 2000-12-16
TR199801195T2 (xx) 1998-10-21
US6750214B2 (en) 2004-06-15
US6642242B2 (en) 2003-11-04
US6103738A (en) 2000-08-15
JP3070958B2 (ja) 2000-07-31
CZ197698A3 (cs) 1999-03-17
SK81698A3 (en) 2000-04-10
US20030220332A1 (en) 2003-11-27
DK0877734T3 (da) 2000-11-20
DE69609353D1 (de) 2000-08-17
CA2236814C (en) 2001-09-18
KR19990076693A (ko) 1999-10-15
ZA9610784B (en) 1998-06-22
PL327610A1 (en) 1998-12-21
EP0877734A1 (en) 1998-11-18
OA10703A (en) 2002-11-28
BR9612263A (pt) 1999-07-13
YU68896A (sh) 1999-07-28
AP9600900A0 (en) 1997-01-31
PT877734E (pt) 2000-12-29
JPH11501668A (ja) 1999-02-09
AP715A (en) 1998-12-30
TNSN96161A1 (fr) 2005-03-15
NZ325248A (en) 1999-09-29
EP0877734B1 (en) 2000-07-12
MA26414A1 (fr) 2004-12-20
HUP9903560A2 (hu) 2000-05-28

Similar Documents

Publication Publication Date Title
CA2236814A1 (en) Quinoline and quinazoline compounds useful in therapy
DK0887344T3 (da) Quinoliner og quinazoliner, som er nyttige ved terapi
NZ336302A (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
NO972909L (no) Substituerte azetidin-2-oner for behandling av atherosklerose
NO980954L (no) Nye-4-(oksyalkoksyfenyl)-3-oksy-piperidiner for behandling av hjerte- og nyreinsuffisiens
BG102792A (bg) Производни на заместени 4-хидроксифенилалканоилови киселини с агонистична активност към рраr-гама
HUP9903836A2 (hu) Új eljárás Cox-2 inhibítor hatású fenil-szubsztituált 2(5H)-furanonok előállítására
BG104287A (en) Halogensubstituted tetracyclic derivatives of tetrahydrofuran
EA199800109A1 (ru) Производные азетидинона для лечения атеросклероза
ATE182889T1 (de) Bicyclische amidinderivate als no-synthetase inhibitoren
NO990335L (no) Arylsykloalkankarboksylestere, anvendelse derav, farmas°ytiske sammensetninger og fremstilling
ATE319680T1 (de) Substituierte 2-benzylamino-2-phenyl- acetamidverbindungen
ATE233242T1 (de) Chinoline und chinazoline verbindungen und ihre therapeutische anwendung
NO960441L (no) Benzopyraner og farmasöytiske forbindelser inneholdende dem
NO995289L (no) Benzimidazol-derivater
EA200101050A1 (ru) Замещенные бензолактамные соединения
TR199801683A2 (xx) Yeni �re t�revleri.
NO914577L (no) Fremgangsmaate for fremstilling av heterocyklisk substituerte piperazinoalkylbenzoksazin- og -tiazinforbindelser
BR9812928A (pt) Novos derivados de 3-oxo-(2h) -1,2,4-triazina, processo de preparação de compostos quìmicos, e, composição farmacêutica
NO982549L (no) 5-naftalen-1-yl-1,3-dioksan-derivater, fremstilling og terapeutisk anvendelse derav
NO983919L (no) 7-fenyl-1,4-diazepanderivater, fremgangsmÕter for fremstilling av disse samt legemidler inneholdende slike forbindelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application